The Lancet Neurology
Fecha de publicación: January 2020
DOI: https://doi.org/10.1016/S1474-4422(19)30438-7
Autores: Claudia Trenkwalder, Brit Mollenhauer
Background: In 2019, many innovative findings were published that will be highly relevant for neuroprotection research in movement disorders. Substantial contributions from basic science have provided a better understanding of the propagation of α-synuclein, which has driven research into new therapies, such as the ongoing trials with antibodies against aggregated α-synuclein.
